ASK-Teva of the tab. kishechnorast. 75 mg No. 30

ASK-Tev's tablets are shown for secondary prevention of a stroke.

For risk reduction:

• death at patients with suspicion of an acute myocardial infarction;
• death at the patients who had a myocardial infarction;
• passing ischemic attacks (TIA) and a stroke at patients with TIA;
• incidence and death in stable and unstable stenocardia.

For prevention:

• thromboses and an embolism after operations on vessels (transdermal transluminal catheter angioplasty (RTSA), endarterectomy of a carotid, aortocoronary shunting (CABG), arteriovenous shunting);
• a deep vein thrombosis and an embolism of lungs after a long immobilization (after surgeries);
• a myocardial infarction at patients with high risk of development of cardiovascular complications (diabetes, controlled arterial hypertension) and to persons with multiple-factor risk of cardiovascular diseases (lipidemia, obesity, smoking, advanced age, etc.).

Warehouse

Active ingredient: acetylsalicylic acid.

1 tablet contains acetylsalicylic acid 75 mg or 100 mg.

Excipients: cellulose microcrystalline (type 102), starch corn, silicon dioxide colloidal, stearic acid.

Cover: methacrylate copolymer dispersion, polysorbate 80, sodium lauryl sulfate, triethyl citrate, talc.

Contraindication

• Hypersensitivity to acetylsalicylic acid, other salicylates or any component of drug.
• Chronic asthma caused by intake of salicylates or NPVP in the anamnesis.
• Acute round ulcers.
• Hemorrhagic diathesis.
• Profound renal failure.
• Profound liver failure.
• Profound heart failure.
Combination with a methotrexate in a dose of 15 mg/week or is more than
• .

Route of administration

is Applied orally.

Tablet entirely, washing down with enough liquid (1/2 glasses of water). Tablets should not be crushed, cut or chewed as provides with an enterosoluble cover of a tablet the prevention irritating influences of medicament on intestines.

For reduction of risk of death at patients with suspicion of an acute myocardial infarction to use medicament in a dose of 75-300 mg a day. Within 30 days after a heart attack to continue to accept a maintenance dose of 75-300 mg a day. In 30 days it is necessary to consider a question of further prevention of a recurrence of a myocardial infarction.

Feature of use

Pregnancy

Should apply with care salicylates during the first and second trimesters of pregnancy. Use of salicylates is contraindicated during the third trimester of pregnancy.

by

for use for children.

Drivers

Researches were not conducted by

.

Overdose

Symptoms of a serious poisoning can develop slowly, for example within 12-24 hours after use. After intake of a dose of ASK up to 150 mg/kg of body weight the development of intoxication of average degree is possible, and at use of a dose> 300 mg/kg of body weight - heavy degree.

Chronic poisoning with salicylates can have the hidden character as symptoms its nonspecific. Moderate chronic intoxication is observed, as a rule, only after repeated receptions of high doses.

significant change of acid-base balance which can differ depending on age of the patient and weight of intoxication testifies To acute intoxication. Its frequent manifestation at children is the metabolic acidosis. Weight of a state cannot be estimated only on the basis of concentration of salicylates in blood plasma. Absorption of acetylsalicylic acid can slow down in connection with a delay of gastric release, forming of concrements in a stomach or in case of administration of medicament in the form of the tablets covered with an enterosoluble cover.

Side effects

In spontaneous messages information on other side reactions on all of dosage forms of ASK arrived, including at oral short-term and long-term therapy therefore determination of categories of frequency according to CIOMS III is impossible.

At patients with severe forms of insufficiency glyukozo-6-fosfatdegidrogenazy observed hemolysis and hemolytic anemia.

. Bleedings, such as PERIOPERATsIONNOY of bleeding, hematoma, nasal bleedings, urogenital bleedings, odontorrhagias were observed. Symptoms can proceed within 4-8 days after cancellation of acetylsalicylic acid.

Seldom or very seldom observed serious bleedings, such as gastrointestinal bleedings, a hemorrhagic stroke, especially at patients with uncontrollable arterial hypertension and/or in case of simultaneous use of anticoagulants that in some cases can potentially threaten life.

Interaction

At use with a methotrexate in a dose of 15 mg/week and increases hematologic toxicity of a methotrexate more (owing to decrease in renal clearance of a methotrexate by anti-inflammatory agents and replacement by methotrexate salicylates from communication with proteins of plasma). So, simultaneous use of a methotrexate (in doses> 15 mg/week) with acetylsalicylic acid contraindicated.

to Store

in the dry, protected from light place at a temperature below 25 °C.

to Store

out of children's reach.

Expiration date - 2 years.